Curium™ has announced the reintroduction of Thallous Chloride TI 201 Injection in the U.S., a radiopharmaceutical used in nuclear cardiology that had seen production cease in 2022. This reavailability aims to diversify diagnostic options for patients undergoing myocardial perfusion evaluations, especially where PET or MRI imaging may not be practical. Curium's decision was influenced by clinician input and significant investments to enhance production infrastructure at its Missouri facility. The reintroduction is expected to improve timely imaging for high-stakes clinical situations, assisting healthcare providers in making critical treatment decisions.
Mon, 27 Jul 2026 12:19:00 GMT | The Manila Times